What is the dosage of Ponatinib?

Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of specific types of leukemia, such as Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), especially in patients who are resistant or intolerant to prior TKI therapies. Its core characteristic is the ability to inhibit a variety of BCR-ABL mutations, including the T315I mutation. The dosage should be adjusted based on the patient’s tolerance and treatment efficacy.

What is the dosage of Ponatinib?

Recommended dosage: The usual starting dose is 45 mg orally once daily, which can be taken with or without food.

Dosage adjustment: In case of severe adverse reactions (e.g., arterial embolism, hepatotoxicity, etc.), the dose may need to be reduced to 30 mg or 15 mg, or treatment may be temporarily discontinued.

Treatment course: Long-term continuous treatment is required until disease progression or intolerable toxicity occurs.

Key precautions for Ponatinib

Cardiovascular risk: Ponatinib may increase the risk of arterial thrombosis (e.g., myocardial infarction, stroke) and venous thrombosis. Close monitoring of blood pressure, blood lipids, and cardiovascular symptoms is necessary.

Liver function monitoring: Regular liver function tests should be performed before and during treatment. Dose adjustment or treatment discontinuation is required if abnormalities are detected.

Bleeding risk: It may induce intracranial hemorrhage or gastrointestinal bleeding. Caution is advised especially when co-administered with anticoagulant drugs.

Embryotoxicity: Patients of childbearing potential must use effective contraceptive measures. The drug is contraindicated during pregnancy.

Common adverse reactions of Ponatinib and their management

Mild reactions:

Rash, fatigue, arthralgia, headache, etc. Generally, treatment discontinuation is not required, and symptoms can be relieved with symptomatic treatment.

Severe reactions:

Arterial/venous thrombosis: Immediate treatment discontinuation and risk assessment are required.

Pancreatitis: 

If abdominal pain or elevated amylase levels occur, treatment should be suspended and supportive care administered.

Hypertension: 

Regular monitoring is needed, and antihypertensive medications should be initiated.